High-Throughput Approaches to Biomarker Discovery and Challenges of Subsequent Validation -- Mass Spectrometry-Based Lipidomics for Biomarker Research -- Flow Cytometry as Platform for Biomarker Discovery and Clinical Validation -- Pentraxin 3 as Biomarker -- Isoprostanes as Biomarkers of Disease and Early Biological Effect -- Fetal Membranes: Potential Source of Preterm Birth Biomarkers -- 1-Hydroxypyrene as a Biomarker for Environmental Health -- Biomarkers of Necrosis and Myocardial Remodeling -- Serum Heat Shock Proteins as Novel Biomarker for Heart -- Failure and Cardiovascular Diseases -- Traditional and Proteomic Biomarkers of Autosomal Dominant -- Polycystic Kidney Disease (ADPKD) -- Biomarker for Amyotrophic Lateral Sclerosis -- Biomarkers of Vector Bites: Arthropod Immunogenic Salivary Proteins in Vector-Borne Diseases Control -- Biomarkers of Graft-Versus-Host Disease

On an annual basis, over 17 million people die due to cardiovascular disease. This represents a third of all global deaths. The World Health Organisation have identified cardiovascular disease as the leading cause of death worldwide. Although many cardiovascular conditions are preventable, there is a need for accurate characterisation and diagnosis of cardiovascular conditions before, during and after treatments. Much of this characterisation entails the use of biological indicators, i.e biomarkers. Biomarkers in Cardiovascular Disease combines detailed information on different cardiovascular conditions and the concomitant application of conventional, new and emerging biomarkers. It covers the latest knowledge, trends and applications. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry